Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 2-year Prospective Study to Evaluate the Onset of Action of Mavenclad® in Subjects With Highly Active Relapsing Multiple Sclerosis (MAGNIFY)

NCT03364036 is registered in ClinicalTrials.gov with Merck KGaA, Darmstadt, Germany as lead sponsor.

NCT NCT03364036
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03364036 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 2-year Prospective Study to Evaluate the Onset of Action of Mavenclad® in Subjects With Highly Active Relapsing Multiple Sclerosis (MAGNIFY)
Lead sponsor
Merck KGaA, Darmstadt, Germany
Phase
Phase 4
Overall status
Completed
Start date
May 28, 2018
Completion date
February 21, 2022
Enrollment
270 (actual)
Sites
54

Conditions

As the registry lists them; a condition with its own page is linked.

multiple sclerosis